High growth momentum investing requires more than just a strong story—it demands a stock that combines accelerating earnings and sales with a healthy technical setup. The idea is to identify companies where the underlying business is firing on all cylinders and, at the same time, the price action is forming a pattern that offers a controlled entry point. By screening for a minimum ChartMill Setup Rating of 7, a Technical Rating above 7, and a High Growth Momentum (HGM) Rating above 4, we are effectively filtering for stocks that exhibit both the fundamental catalysts and the technical consolidation needed for a potential breakout.
One name that appears in this screen is Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT). The company, which develops and commercializes topical treatments for dermatological conditions like plaque psoriasis and atopic dermatitis, is currently passing all three key tests with room to spare.
High Growth Momentum Profile
The High Growth Momentum Rating of 6 out of 10 is a meaningful threshold. As noted in the methodology, a score of 6 or higher is already considered quite good, and it tells us the stock is displaying the kind of short-term earnings momentum typical of CANSLIM and Minervini-style screens. The reasons for this score are visible in the underlying data.
Year-over-year EPS growth over the trailing twelve months stands at 97.1%. Even more striking is the acceleration story: when looking at the most recent reported quarter (Q-2), EPS growth was 118.2%. That number jumped to 244.4% in the prior quarter before settling back to 55.0% in the latest quarter. While the most recent quarter shows a deceleration from those peak levels, the sequential growth pattern remains strong, and the stock still managed to beat EPS estimates by an average of 45.8% over the last four quarters, with three positive surprises out of four.
On the revenue side, the picture is equally strong. TTM revenue growth is about 95.3%, and the company has beaten revenue estimates in every one of the last four quarters, with an average beat of 8.7%. The sales growth trajectory, however, tells a more cautious story. While growth rates were as high as 164.1% three quarters ago, they have steadily decelerated to the current 60.1%. A deceleration in revenue growth is a factor the HGM rating weighs negatively, which likely prevents the score from climbing even higher. Still, maintaining 60% top-line growth while turning free cash flow positive—FCF per share is now $0.14, with 108.5% growth—shows the business is maturing effectively.
Technical Strength and Setup Quality
Strong fundamentals are only half of the equation. The technical picture for ARQT is exceptional. The stock earns a perfect Technical Rating of 10 out of 10. It has outperformed 94% of all stocks over the past year, with a relative strength rating of 94.2. Both the short-term and long-term trends are positive, and the price is trading above its 20, 50, and 200-day simple moving averages, all of which are rising except the 100-day SMA.
The Setup Rating comes in at 8 out of 10, which indicates the stock is in a period of price consolidation with reduced volatility. According to the detailed technical analysis report, the stock has been trading in a range between roughly $25.25 and $29.84 over the last month. This consolidation is taking place near the upper end of the 52-week range, which is a constructive sign. The technical report identifies a clear support zone between $25.31 and $25.81, built from moving averages and trend lines across multiple timeframes. Just above the current price of $27.90, there is resistance at $28.10 and a zone from $28.57 to $28.63.
This setup is precisely the kind of pattern growth investors look for. The stock has already demonstrated notable earnings momentum, and it is now pausing in a tight range, compressing energy for the next leg higher. A breakout above the $28.63 resistance zone would confirm the pattern and provide a potential entry point.
Why This Combination Matters
The combination of a high HGM rating with strong technical and setup scores is what makes this screen effective. A stock can have spectacular growth, but if it is already extended, the risk of buying at the top is significant. Conversely, a stock can have a beautiful chart pattern, but if the business fundamentals are deteriorating, the breakout is more likely to fail.
ARQT sits at the intersection of these two conditions. The earnings and sales numbers confirm the business is expanding at an impressive rate, while the technical setup shows the stock has recently digested its gains and may be ready to resume its uptrend. For investors following a disciplined growth strategy, this is the kind of alignment that reduces risk and improves the probability of a successful trade.
Screening for More Opportunities
This is not the only name meeting these criteria. You can run this same screen yourself to identify other stocks that combine high growth momentum with a strong technical breakout pattern. To explore the full list of current candidates, check out the High Growth Momentum Breakout Setups Screen to see more results.
This article is for informational purposes only and does not constitute investment advice. Always conduct your own research and consider your risk tolerance before making any trading decisions.
Read full article here »
View the Zacks #1 Rank List
Arcutis Biotherapeutics (NASDAQ:ARQT) Shows High Growth Momentum and Breakout Setup
High growth momentum investing requires more than just a strong story—it demands a stock that combines accelerating earnings and sales with a healthy technical setup. The idea is to identify companies where the underlying business is firing on all cylinders and, at the same time, the price action is forming a pattern that offers a controlled entry point. By screening for a minimum ChartMill Setup Rating of 7, a Technical Rating above 7, and a High Growth Momentum (HGM) Rating above 4, we are effectively filtering for stocks that exhibit both the fundamental catalysts and the technical consolidation needed for a potential breakout.
One name that appears in this screen is Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT). The company, which develops and commercializes topical treatments for dermatological conditions like plaque psoriasis and atopic dermatitis, is currently passing all three key tests with room to spare.
High Growth Momentum Profile
The High Growth Momentum Rating of 6 out of 10 is a meaningful threshold. As noted in the methodology, a score of 6 or higher is already considered quite good, and it tells us the stock is displaying the kind of short-term earnings momentum typical of CANSLIM and Minervini-style screens. The reasons for this score are visible in the underlying data.
Year-over-year EPS growth over the trailing twelve months stands at 97.1%. Even more striking is the acceleration story: when looking at the most recent reported quarter (Q-2), EPS growth was 118.2%. That number jumped to 244.4% in the prior quarter before settling back to 55.0% in the latest quarter. While the most recent quarter shows a deceleration from those peak levels, the sequential growth pattern remains strong, and the stock still managed to beat EPS estimates by an average of 45.8% over the last four quarters, with three positive surprises out of four.
On the revenue side, the picture is equally strong. TTM revenue growth is about 95.3%, and the company has beaten revenue estimates in every one of the last four quarters, with an average beat of 8.7%. The sales growth trajectory, however, tells a more cautious story. While growth rates were as high as 164.1% three quarters ago, they have steadily decelerated to the current 60.1%. A deceleration in revenue growth is a factor the HGM rating weighs negatively, which likely prevents the score from climbing even higher. Still, maintaining 60% top-line growth while turning free cash flow positive—FCF per share is now $0.14, with 108.5% growth—shows the business is maturing effectively.
Technical Strength and Setup Quality
Strong fundamentals are only half of the equation. The technical picture for ARQT is exceptional. The stock earns a perfect Technical Rating of 10 out of 10. It has outperformed 94% of all stocks over the past year, with a relative strength rating of 94.2. Both the short-term and long-term trends are positive, and the price is trading above its 20, 50, and 200-day simple moving averages, all of which are rising except the 100-day SMA.
The Setup Rating comes in at 8 out of 10, which indicates the stock is in a period of price consolidation with reduced volatility. According to the detailed technical analysis report, the stock has been trading in a range between roughly $25.25 and $29.84 over the last month. This consolidation is taking place near the upper end of the 52-week range, which is a constructive sign. The technical report identifies a clear support zone between $25.31 and $25.81, built from moving averages and trend lines across multiple timeframes. Just above the current price of $27.90, there is resistance at $28.10 and a zone from $28.57 to $28.63.
This setup is precisely the kind of pattern growth investors look for. The stock has already demonstrated notable earnings momentum, and it is now pausing in a tight range, compressing energy for the next leg higher. A breakout above the $28.63 resistance zone would confirm the pattern and provide a potential entry point.
Why This Combination Matters
The combination of a high HGM rating with strong technical and setup scores is what makes this screen effective. A stock can have spectacular growth, but if it is already extended, the risk of buying at the top is significant. Conversely, a stock can have a beautiful chart pattern, but if the business fundamentals are deteriorating, the breakout is more likely to fail.
ARQT sits at the intersection of these two conditions. The earnings and sales numbers confirm the business is expanding at an impressive rate, while the technical setup shows the stock has recently digested its gains and may be ready to resume its uptrend. For investors following a disciplined growth strategy, this is the kind of alignment that reduces risk and improves the probability of a successful trade.
Screening for More Opportunities
This is not the only name meeting these criteria. You can run this same screen yourself to identify other stocks that combine high growth momentum with a strong technical breakout pattern. To explore the full list of current candidates, check out the High Growth Momentum Breakout Setups Screen to see more results.
This article is for informational purposes only and does not constitute investment advice. Always conduct your own research and consider your risk tolerance before making any trading decisions.
Read full article here »